Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
Meiji Seika Pharma announced Tuesday that it plans to apply in Japan to sell its self-amplifying mRNA vaccine for Covid-19 and supply it for the fall/winter season.
Arcturus Announces Fourth Quarter and Fiscal Year 2023 Financial Progress
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
Arcturus Receives Orphan Medicinal Product Designation from the EC for ARCT-032
Arcturus to Report Fourth Quarter and Full Year 2023 Financial Results
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate
SAN DIEGO, Jan. 5, 2024 /PRNewswire/ -- PassPort Technologies, Inc. (PPTI), led by President and CEO Tomoyuki Fujisawa in California, USA is pleased to announce the initiation of a collaborative research endeavor with Arcturus Therapeutics (ARCT). This research collaboration is focused on evaluating innovative mRNA formulations and transdermal delivery mechanisms for vaccines and therapeutics.
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates
Exelixis and Arcus Announce Trial Collaboration to Evaluate Zanzalintinib